Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Nuvation Bio Inc.NYSE: NUVB

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares of 348.77M shares rose 2.4% year over year, behind the +7.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.4% toward the trailing-twelve-month pace of +7.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
348.77M+0.4% QoQ
Last fiscal yearDec 2025
341.54M+27.1% YoY
LTMJun 2026
345.71M+7.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.4%——
1 year+27.1%——
3-year CAGR+16.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
341.54M USD
Year-over-year change
+27.1%
4-year CAGR
+14.6%

Weighted Avg Shares vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's LTM Jun 2026 weighted avg shares of 345.71M shares is the highest of the 11 companies compared; the peer median is 75.89M shares.
  • Its year-over-year change of +7.2% is the 8th highest of 11, against a peer median of +11.8%.
  • Over three fiscal years its annual growth of +16.4% compares with a peer median of +15.9%.
NUVB Competitors Peer median
Weighted Avg Shares for NUVB and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026345.71M +7.2%+16.4%
ABCLAbCellera Biologics Inc.LTM Sep 2026306.35M +3.0%+1.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026200.88M +19.9%+34.5%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026133.21M -5.4%-1.8%
VRDNViridian Therapeutics, Inc.LTM Jun 202694.17M +21.7%+38.3%
EWTXEdgewise Therapeutics, Inc.LTM Sep 202679.43M -20.2%+24.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
VERAVera Therapeutics, Inc.LTM Jun 202667.85M +14.4%+34.2%
GPCRStructure Therapeutics Inc.LTM Jun 202665.7M +14.4%+17.4%
JANXJanux Therapeutics, Inc.LTM Mar 202662.14M +9.2%+14.3%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
Peer median (excluding NUVB) 75.89M+11.8%+15.9%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007.87M62.9M
Cost of Revenue0007.08M8.44M
Gross Profit000795K54.46M
Gross Margin———10.1%86.6%
Research & Development69.04M87.82M71.29M524.19M115.11M
Selling, General & Admin24.28M31.92M28.53M69.23M151.56M
Operating Expenses93.32M119.73M99.82M593.42M267.52M
Depreciation & Amortization184K199K222K683K1.74M
EBITDA(86.66M)(104M)(75.58M)(566.92M)(189.21M)
EBITDA Margin———-7200.7%-300.8%
Operating Income(93.32M)(119.73M)(99.82M)(592.63M)(213.06M)
Operating Margin———-7527.3%-338.7%
Interest Income2.96M7.45M24.61M27.06M21.43M
Interest Expense000341K13.68M
Other Income / Expenses6.47M15.54M24.02M24.69M8.44M
Income Before Tax(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Pre-Tax Margin———-7213.8%-325.3%
Income Tax Expense00000
Net Income(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Net Margin———-7213.8%-325.3%
EPS (Basic)(0.44)(0.48)(0.35)(2.11)(0.60)
EPS (Diluted)(0.44)(0.48)(0.35)(2.11)(0.60)
Weighted Avg Shares197.89M216.72M218.88M268.77M341.54M
Weighted Avg Shares (Diluted)197.89M216.72M218.88M268.77M341.54M

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.